Literature DB >> 16893689

Liquid chromatography with tandem mass spectrometry for the simultaneous determination of baicalein, baicalin, oroxylin A and wogonin in rat plasma.

Young Hoon Kim1, Dong Won Jeong, In Bok Paek, Hye Young Ji, Youn-Chul Kim, Dong Hwan Sohn, Hye Suk Lee.   

Abstract

A rapid, sensitive and selective liquid chromatography-tandem mass spectrometric (LC-MS/MS) method for the determination of baicalein, baicalin, oroxylin A and wogonin, Scutellaria baicalensis active components in rat plasma was developed. After liquid-liquid extraction with 2-(3,4-dimethoxy-phenyl)-5,7-dihydroxy-chromen-4-one as internal standard, baicalein, baicalin, oroxylin A and wogonin were eluted from an Atlantis C(18) column within 7 min with isocratic mobile phase consisting of methanol and 0.1% formic acid (60:40, v/v). The analytes were detected using an electrospray ionization tandem mass spectrometry in the multiple reaction monitoring (MRM) mode. The standard curves were linear (r=1.000) over the concentration ranges of 5-500 ng/ml for baicalein, wogonin and oroxylin A and 5-5000 ng/ml for baicalin. The coefficients of variation and relative errors of baicalein, wogonin, oroxylin A and baicalin for intra- and inter-assay at three or four quality control (QC) levels were 0.8-6.1% and -4.0 to 5.8%, respectively. The lower limits of quantification for baicalein, wogonin, oroxylin A and baicalin were 5ng/ml using 50 microl of plasma sample. This method was successfully applied to the pharmacokinetic study of baicalein, baicalin, wogonin and oroxylin A after an intravenous administration of Scutellariae radix extract to male Sprague-Dawley rats.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16893689     DOI: 10.1016/j.jchromb.2006.07.021

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  7 in total

1.  An overview and comparison of a recombinant antigen-binding fragment and an antigen-binding fragment from a monoclonal antibody against wogonin glucuronide.

Authors:  Madan Kumar Paudel; Seiichi Sakamoto; Hiroyuki Tanaka; Satoshi Morimoto
Journal:  J Nat Med       Date:  2017-06-16       Impact factor: 2.343

2.  Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS).

Authors:  Wei Zhang; Muhammad W Saif; Ginger E Dutschman; Xin Li; Wing Lam; Scott Bussom; Zaoli Jiang; Min Ye; Edward Chu; Yung-Chi Cheng
Journal:  J Chromatogr A       Date:  2010-07-21       Impact factor: 4.759

3.  Qualitative and quantitative determination of 15 main active constituents in Fructus Sophorae pill by liquid chromatography tandem mass spectrometry.

Authors:  Xu-Ran Zhi; Zhi-Yong Zhang; Pei-Pei Jia; Xiao-Xu Zhang; Lin Yuan; Ning Sheng; Lan-Tong Zhang
Journal:  Pharmacogn Mag       Date:  2015 Jan-Mar       Impact factor: 1.085

4.  Comparative pharmacokinetics of baicalin, wogonoside, baicalein and wogonin in plasma after oral administration of pure baicalin, radix scutellariae and scutellariae-paeoniae couple extracts in normal and ulcerative colitis rats.

Authors:  Zhen-Qiu Zhang; Wei Liua; Li Zhuang; Jing Wang; Shuai Zhang
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

Review 5.  Applications of HPLC/MS in the analysis of traditional Chinese medicines.

Authors:  Miao Li; Xiao-Fang Hou; Jie Zhang; Si-Cen Wang; Qiang Fu; Lang-Chong He
Journal:  J Pharm Anal       Date:  2012-01-30

Review 6.  Antiviral Properties of Baicalin: a Concise Review.

Authors:  Kunwei Li; Yiyu Liang; Ao Cheng; Qi Wang; Ying Li; Haocheng Wei; Changzheng Zhou; Xinhuan Wan
Journal:  Rev Bras Farmacogn       Date:  2021-10-06       Impact factor: 2.010

Review 7.  Advances of modern chromatographic and electrophoretic methods in separation and analysis of flavonoids.

Authors:  E-Hu Liu; Lian-Wen Qi; Jun Cao; Ping Li; Chang-Yin Li; Yong-Bo Peng
Journal:  Molecules       Date:  2008       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.